Antisense platform with royalty economics — 98.8% gross margin. SPINRAZA royalties provide base; TRYNGOLZA (first wholly-owned launch) tests commercial capability. Pipeline (pelacarsen for Lp(a), donidalorsen for HAE) has blockbuster potential.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$13.52BSnapshot value
TRYNGOLZA FCS launch trajectory, pelacarsen Lp(a) Ph3 CVOT readout (HORIZON), donidalorsen HAE Ph3 completion, WAINUA ATTRv-PN ex-US expansion
1. TRYNGOLZA commercial disappointment — FCS market too small. 2. Pelacarsen HORIZON trial fails — Lp(a) thesis breaks. 3. SPINRAZA royalty cliff from Biogen SMA competition (Roche risdiplam, gene therapy). 4. Donidalorsen HAE fails vs established competition. 5. Cash burn accelerates — dilution before profitability.
Elevated retail discussion driven by 160% 1Y return and TRYNGOLZA launch. High short interest (10.3 ratio) attracts squeeze narratives.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed